Category: Latest Posts

Healthcare costs continue to escalate, placing a significant burden on families nationwide. Innovations like GLP-1 medications for preventative care and generative AI for ongoing disease management are emerging as promising tools to control these expenses. Chronic disease, particularly obesity, remains a primary driver of healthcare spending. GLP-1 therapies not only help with weight reduction but also slow the progression of long-term conditions. For those already managing chronic illnesses, integrating generative AI with home monitoring devices allows for continuous tracking and faster detection of health issues, enabling clinicians to make timely treatment adjustments. There is growing discussion around expanding GLP-1 coverage through federal programs and improving connectivity between home health technology and clinician-guided AI. With national healthcare spending projected to hit $9 trillion by 2034, experts are calling for broader access to these solutions to help manage costs. As we evaluate financial strategies for the future, understanding the impact of healthcare innovations is essential.

There’s an ongoing national discussion about insurance coverage for a breast cancer biomarker test, specifically related to DCIS—a form of non-invasive breast cancer found in milk ducts. What makes DCIS challenging is its unpredictable nature, and doctors often need more clarity to determine which patients might actually benefit from radiation. The test in question offers a deeper look at tumor biology, aiming to predict both the chance of recurrence and whether radiation would make a difference. Supporters believe this could mean more personalized treatment—helping some women avoid unnecessary radiation and guiding others toward it when beneficial. However, the question remains: do these biomarker tests provide enough additional value over current methods to warrant national insurance coverage? While federal agencies acknowledge the innovation, these lab tests aren’t yet included in the new accelerated coverage pathway. Another advisory panel will meet on October 13 to consider next steps. In my work designing benefit plans, I understand how policy decisions like these can impact both individuals and organizations—especially when it comes to coverage for innovative medical solutions.

Cashless health insurance offers a streamlined approach for global policyholders: insurers pay approved hospital bills directly to the provider, provided the treatment fits within your policy’s terms, limits, and authorizations. Here’s how it typically works: you select an eligible hospital, share your policy details, and the hospital submits a pre-authorization for diagnosis, treatment, and costs. Once the insurer reviews and approves eligible care, the hospital manages most of the billing process, submitting documents at discharge for direct settlement of covered expenses—leaving you responsible only for any excluded costs.

Families with global coverage benefit from reduced upfront payments, quicker access to care, and less paperwork, as the hospital coordinates billing with your insurer. The key difference between cashless and reimbursement claims is when payment happens, so it’s essential to review the hospital network, waiting periods, co-payments, limits, exclusions, and claim requirements before seeking treatment. Just as in executive benefit planning, knowing the details of your policy can make all the difference in how smoothly the process runs.

Researchers said the avg. largest insurer held ~64% of a state's market, while the top three controlled ~91%, raising questions about how competitive coverage is.
They argued limited competition and adverse selection can push insurers to favor healthier customers, making stable, customer-friendly markets harder to sustain nationwide.
New insurers may win early enrollment with lower premiums, but smaller patient pools can weaken provider negotiations, raise expenses, and make long-term competition difficult.
In concentrated markets, plans may use perks to attract healthier people or make expensive care harder through higher copays and extra paperwork.
The proposed path is broader oversight: policymakers can rethink market rules so competition works better for customers while limiting distortions tied to preexisting-condition protections.

There’s a growing conversation among retirees about the spend-it-all approach—using their savings to create meaningful experiences and give generously, rather than holding back out of habit or fear. While this mindset can help retirees avoid underspending, it’s crucial to have a clear plan in place. According to a recent survey, about half of Americans don’t have a written financial plan, and this approach requires precise budgeting and disciplined savings to work effectively. Interestingly, many retirees actually withdraw less than the familiar 4% guideline, and research has shown that some households finish retirement with nearly all of their starting assets untouched. However, spending and gifting assets earlier can come with trade-offs: larger withdrawals may reduce tax efficiency, and heirs might miss out on the step-up in basis advantage. One thoughtful strategy is to secure permanent life insurance earlier in life—this can provide heirs with a tax-free benefit and, if needed, offer the owner access to policy value. As someone who works with Executive Bonus Plans, Defined Benefit Plans, and Non-Qualified Deferred Compensation Plans, I see how aligning your retirement spending with these tools can create both flexibility and security for you and your loved ones.

GLP-1 medications have made headlines for their impact on weight management, but how are these drugs actually covered by health plans in the US? Generally, coverage is far more common when these medications are prescribed for diabetes or related conditions. However, if the prescription is strictly for weight loss, coverage becomes much more limited. Many health plans set requirements like prior authorization and specific BMI thresholds before approving GLP-1s for weight management. In the individual insurance market, weight-loss coverage for these drugs is rare. Employer plans show more flexibility: about 60% cover GLP-1s for diabetes, while only 35% extend coverage to both diabetes and weight loss. For those on the federal senior health program, weight-loss-only coverage is still excluded from the standard benefit, though a pilot program is now offering select GLP-1s for $50 per month. State and federal programs vary widely, so it's important to review your plan’s details and stay alert for new developments. Understanding how these medications fit into your benefits strategy is key, especially as plan rules evolve.